China SXT Pharmaceuticals (SXTC) Accounts Payables (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Accounts Payables for 9 consecutive years, with $497648.0 the latest figure, recorded in Q1 2026.

• Quarterly Accounts Payables fell 57.04% year-over-year to $497648.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $497648.0 (down 57.04% YoY) and the FY2026 annual result came in at $497648.0, down 57.04% from the prior year.
• Accounts Payables retreated to $497648.0 in Q1 2026 per SXTC's latest filing, from $530662.0 in the prior quarter.
• Over the last five years, Accounts Payables for SXTC reached as high as $3.5 million in Q1 2022 and fell as low as $497648.0 in Q1 2026.
• A 5-year average of $1.4 million and a median of $1.3 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables gained 26.36% — and 2025, when it tumbled 68.08%.
• Year by year, Accounts Payables stood at $1.6 million in 2022, then fell by 15.72% to $1.3 million in 2023, then climbed by 26.36% to $1.7 million in 2024, then slumped by 68.08% to $530662.0 in 2025, then declined by 6.22% to $497648.0 in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $497648.0, $530662.0, and $1.2 million for Q1 2026, Q3 2025, and Q1 2025 respectively.